Zimbabwe’s Mugabe Hospitalized in Singapore Since April
(Bloomberg) -- Robert Mugabe, who ruled Zimbabwe for 38 years until being ousted by the army in late 2017, is under observation in the hospital in Singapore and has been there since April.
Mugabe, 95, has periodically visited Singapore for medical treatment over the last few years. Little information has been given over what ails him other than that he suffers from eye cataracts. The length of his stay in the hospital hadn't been previously disclosed.
“Unlike in the past when the former president would require just a month for this, his physicians this time around determined that he be kept under observation for much longer,” said Emmerson Mnangagwa, Zimbabwe's current president, in a statement. “His condition is remarkably stable for his age. He is responding very well to all treatment.”
Mnangagwa said he sent a team of physicians and civil servants to check on his condition.
Mugabe took over as leader of Zimbabwe in 1980 when the country won independence from the U.K. after a bitter liberation war against the white-minority government. Mnangagwa served in his government from independence and was one of his closest allies before they fell out a few month prior to Mugabe's ousting.
To contact the reporters on this story: Antony Sguazzin in Johannesburg at asguazzin@bloomberg.net;Godfrey Marawanyika in Harare at gmarawanyika@bloomberg.net
To contact the editor responsible for this story: Paul Richardson at pmrichardson@bloomberg.net
©2019 Bloomberg L.P.
-
A New Samvat Wishlist: Inclusive Prosperity And Human Development
India has strengthened its economic foundations through infrastructure, digital access and enterprise. Its next growth chapter must deepen productivity, create better livelihoods and widen participation in prosperity.
-
Love, Sex Aur Dhokha: The Audacious Plot To Spy On Jensen Huang
A Taipei dinner, a Singapore chip buyer and a suspected Chinese asset: inside the alleged spy operation that got close to NVIDIA's Jensen Huang.
-
Ten Things I Learnt This Samvat
Patience can be a trap. Cheap stocks can stay cheap. Leverage can wipe you out. What did Samvat 2082 teach us? Niraj Shah writes on 10 lessons from the year gone by.
-
Talking Points This Week: Tech Nerves, FII Buying, And A Faraway Banking Shock
The global markets are not shining this Diwali. The exception in the large markets is, India.
-
Midterm Rally Lasted A Day. The Hard Reality Of A Divided US May Last Two Years | Opinion
Between a contested AI boom, a debt ceiling that arrives in 2027 and a president with every incentive to act alone, the next two years may prove more volatile than the first day's rally suggests.
-
Blue Wave Will Derail the AI Trade but Won't Dismantle the AI Era | Unhedged Position
The Democrats' sweep of the US Congress will see politics collide with economic forces both over the long and short term.
-
It's Time To Take The GST Council's Bet On Trust Global
Payment records can prove India's services exports, and clear, proportionate rules can bring foreign digital sellers into the tax net.
-
Opinion | India at 38: From Innovation Overperformer to Innovation Powerhouse
India now has 453 VC-backed deep science startups, 18 of them late-stage, after 117 percent growth since 2020. Laurus Labs, at USD 9.3 billion, is the most valuable deep science company in any middle-income economy outside China.
-
Navigating Energy Crossroads: S Jaishankar's Call For Diversified Supply Chains At G20 Ministerial Meeting
As geopolitical fault lines continue to test maritime trade routes and commodity flows, Jaishankar's message remains pertinent: true economic resilience requires open markets, protected transit lines, and a genuine commitment to multilateral cooperation rather than coercion.
